| 39th week of 2021 patent applcation highlights part 27 |
| Patent application number | Title | Published |
|---|
| 20210300820 | Non-Combustible, Breathable Membrane - A coated textile contains a web based on glass fibres having a back face, a front face and at least one edge. The front face is covered with a coating layer based on silicone and back face is capable of being bonded to a support. The coating layer has a thickness between 5 μm and 250 μm and includes at least one inorganic flame retardant compound in a quantity which is sufficient for the coated textile to have a gross calorific value of less than or equal to 3 MJ/kg, the inorganic flame retardant compound having a D50 granule size of less than 50 μm. | 2021-09-30 |
| 20210300821 | SYSTEM AND METHOD OF CURING ADHESIVE DURING ASSEMBLY OF GLASS SYRINGES - A method for curing adhesive during assembly of glass syringes, including: dispensing adhesive onto a glass syringe; and curing the adhesive using a UV LED line array. The method may include one or both of pre-curing the adhesive using a UV LED spot and heating at least one of the glass barrel, needle and adhesive at one or more points during the method. A system for curing an adhesive during assembly of a glass syringe, the system including: a dispensing station for dispensing the adhesive onto a glass barrel and needle; a pre-curing station for pre-curing the adhesive; a curing station for curing the adhesive; and at least one infrared heater for heating at least one of the glass barrel, needle and adhesive at one or more points in the system. The glass syringe may be operated on by a subset of the stations in the system. | 2021-09-30 |
| 20210300822 | GLASS PANEL UNIT AND METHOD FOR MANUFACTURING THE GLASS PANEL UNIT - A glass panel unit includes a first glass pane, a second glass pane, a frame member, a vacuum space, and a gas adsorbing layer. The gas adsorbing layer is formed to cover at least one of the first glass pane or the second glass pane. The gas adsorbing layer contains a getter material. | 2021-09-30 |
| 20210300823 | CONCRETE ADMIXTURE - A defoamed aqueous composition including 5 to 75 weight-% of at least one anionic polymer, 0.05 to 5 weight-% of at least one water insoluble liquid defoamer and 0.005 to 3 weight-% of at least one polysaccharide, based on 100 weight-% of the composition. The composition gives predictable air content in non-air entrained and air-entrained mortar and concrete. | 2021-09-30 |
| 20210300824 | COMPOSITION FOR A HEAT TREATMENT JIG, AND METHOD OF MANUFACTURING A HEAT TREATMENT JIG - A composition for a heat treatment jig includes: alumina at a weight ratio within the range of 5% or more and 25% or less; mullite at a weight ratio within the range of 0% or more and 35% or less; cordierite at a weight ratio within the range of 15% or more and 35% or less; spinel at a weight ratio within the range of 0% or more and 35% or less; and fused silica at a weight ratio within the range of 15% or more and 50% or less. The composition for a heat treatment jig is used for the method of manufacturing a heat treatment jig, such as a heat treatment container. | 2021-09-30 |
| 20210300825 | DIELECTRIC CERAMIC COMPOSITION AND ELECTRONIC COMPONENT - Provided is a dielectric ceramic composition comprising a main component of forsterite and calcium strontium titanate. A content ratio of forsterite in the main component is from 84.0 to 92.5 parts by mole, and a content ratio of calcium strontium titanate is from 7.5 to 16.0 parts by mole. (Sr+Ca)/Ti in the calcium strontium titanate is from 1.03 to 1.20 in terms of a molar ratio. With respect to a total of 100 parts by mass of the main component and a subcomponent except for Li-containing glass, from 2 to 10 parts by mass of Li-containing glass is added. The Li-containing glass includes Al | 2021-09-30 |
| 20210300826 | METHOD FOR PRODUCING SOLID COMPOSITION AND METHOD FOR PRODUCING FUNCTIONAL CERAMIC - A method for producing a solid composition according to the present disclosure is a method for producing a solid composition that is used for forming a functional ceramic having a first crystal phase. The method for producing a solid composition includes: producing an oxide composed of a second crystal phase different from the first crystal phase; and mixing the oxide and an oxo acid compound. | 2021-09-30 |
| 20210300827 | DOPED PEROVSKITE BARIUM STANNATE MATERIAL WITH PREPARATION METHOD AND APPLICATION THEREOF - Disclosed herein is a doped perovskite barium stannate material, which has a chemical general formula of BaA | 2021-09-30 |
| 20210300828 | BLACK SINTERED BODY AND METHOD FOR PRODUCING THE SAME - A sintered body includes a solid solution containing cobalt and iron, with the balance being zirconia. The total content of cobalt in terms of CoO and iron in terms of Fe | 2021-09-30 |
| 20210300829 | CRYSTALLINE SILICON CARBIDE FIBER AND METHOD FOR MANUFACTURING SAME, AND CERAMIC COMPOSITE SUBSTRATE - A crystalline silicon carbide fiber containing silicon carbide and boron nitride, the crystalline silicon carbide fiber having a content of Si of 64% to 72% by weight, a content of C of 28% to 35% by weight, and a content of B of 0.1% to 3.0% by weight, and including, at a surface portion, a composition gradient layer in which a content of silicon carbide increases while a content of boron nitride decreases toward a depth direction. | 2021-09-30 |
| 20210300830 | PROCESS FOR MARKING A REFRACTORY CERAMIC PART - A process for marking a surface of a refractory ceramic part, known as the “surface to be marked.” The part has a microstructure of grains including more than 50% by mass of ZrO | 2021-09-30 |
| 20210300831 | COMPOSITIONS COMPRISING SOLID THIOSULFATES, POLYSULFIDES AND/OR (BI)SULFITES AND METHODS FOR PREPARING SAME - Provided in the invention are thiosulfate-urea based products (IIa) and/or a polysulfide-urea based products (IIb) and/or a (bi)sulfite-urea based products (IIc) suitable for use in fertilizers and comprising: one or more urea-containing compounds (a), one or more compounds (b), optionally, one or more urease (c1) and/or nitrification (c2) inhibitors that are different from compounds (b), and/or optionally, one or more additives (d) that are different from any of the above compounds, wherein the amount of water (e) in the product (II) is less than about 10 wt %, preferably less than about 5 wt %, wherein compounds (a) are selected from urea (a1) and/or from urea-aldehyde products (a2) and/or from urea-triazone compounds (a3), wherein compounds (b) are selected from thiosulfates (b1) and/or from polysulfides (b2) and/or from (bi)sulfites (b3). An advantage of products of the invention is that only minimal amounts of degradation products of compounds (b) are formed. Products of the invention can be made in various forms and in different ways. All of the materials of the invention are suitable for use in fertilizers and blend well with solid and liquid fertilizers standardly used. | 2021-09-30 |
| 20210300832 | Micronutrient Concentrate and use thereof - The invention relates to a liquid, substantially anhydrous concentrate comprising dissolved micronutrients in an amount of between 0.3 wt %-5 wt % of metal ions, chosen from zinc, manganese, selenium, iron, copper, cobalt, molybdenum, and magnesium and mixtures of these, 0.3 wt % carboxylic acid compound which is soluble in glycol, and at least 40 wt % of a glycol compound wherein the glycol compound is a compound comprising a α,ω-ethyldiolgroup, optionally comprising ethyl-ether groups. | 2021-09-30 |
| 20210300833 | BIOFERTILIZER FORMULATION FROM ALGAE AND RELATED METHODS - A biofertilizer is disclosed that include specific formulations of algae biomass and a mycorrhizal fungus. This biofertilizer may be a useful way of utilizing algae biomass created for carbon sequestration purposes for a productive agricultural purpose. The combination of algae biomass and mycorrhizal fungus may provide advantageous effects to a crop, as the algae may be a nutrient source for both the crop itself and also for the mycorrhizal fungus that allows the fungus to grow and form a mycorrhizal relationship with the root system of the crop. The biofertilizer may be pelletized with rice hull filler and have a specific range of moisture content, so as to be compatible to agricultural fertilizer delivery equipment. Methods of manufacturing the pelletize biofertilizer are also provided. | 2021-09-30 |
| 20210300834 | METHODS AND COMPOSITIONS FOR INCREASING THE AMOUNTS OF PHOSPHORUS AVAILABLE FOR PLANT UPTAKE FROM SOILS - The present invention relates to a method of enhancing growth conditions for plants by growing the plants in soil containing, in proximity to the plant roots, both a phosphorus source and at least two strains of the fungus | 2021-09-30 |
| 20210300835 | A Bacterial Composition Capable of Degrading Complex Carbohydrates - The present invention relates to a bacterial composition, and can be used to augment compost. According to the present invention, there is provided a bacterial composition comprising at least one strain of | 2021-09-30 |
| 20210300836 | JOINT CONTROL METHOD FOR NITROGEN AND PHOSPHOROUS EMISSIONS IN FARMLANDS - The present disclosure provides a joint control method for nitrogen and phosphorus emissions in farmlands, comprising: reducing nitrogen and phosphorus input during crop sowing or planting by applying composite organic material and chemical fertilizer, wherein the composite organic material comprises: 200-250 parts of edible fungi residues, 300-350 parts of charcoal and 5-10 parts of rhamnolipid; constructing a nitrogen-phosphorus retaintion layer by utilizing composite microbial agent in combination with 150 parts of edible fungi residues and 20 parts of straw-based hydrogel; constructing a barrier layer by utilizing composite material, and controlling downward leaching of nitrogen and phosphorus that are not absorbed by crops, wherein the composite material of the barrier layer comprises: 25-35 parts of straw-based hydrogel, 20-30 parts of edible fungi residues, 35-55 parts of bentonite and 5-10 parts of corn flour. | 2021-09-30 |
| 20210300837 | FERTILIZER POUCH - The present invention relates to methods and compositions for a fertilizer pouch comprised of hot water soluble polyvinyl alcohol. Methods and compositions for reducing leached nutrients are also provided including but not limited to: Iron, Manganese, Copper, Bicarbonate, Zinc, Phosphorus, Molybdenum, Ammonia, Nitrogen, Calcium, Potassium, Sulfate, Magnesium, Sodium, Chloride, Inorganic Nitrogen, and Total Nitrogen. Further, methods and compositions for treating a plant are provided. | 2021-09-30 |
| 20210300838 | PBX COMPOSITION - The invention relates to a cast explosive composition. There is provided a precure castable explosive composition comprising an explosive material, a polymerisable binder, said cross linking reagent comprising at least two reactive groups each of which is protected by a labile blocking group. | 2021-09-30 |
| 20210300839 | METHOD FOR QUENCHING PEROXYCARBOXYLIC ACID RUNAWAY REACTIONS - Systems for quenching peroxycarboxylic acid and peroxide chemistry runaway reactions provide safe and efficacious systems to prevent uncontrolled runaway reactions, such as decomposition reactions, of peroxycarboxylic acid and peroxide chemistry compositions are disclosed. The systems provide prompt detection and dispensing of a stabilizer into a tank or other storage vessel containing a peroxide composition, peroxycarboxylic acid composition or a peroxycarboxylic acid-forming composition to stop a runaway reaction. Methods for quenching peroxide and peroxycarboxylic acid runaway reactions are also disclosed. | 2021-09-30 |
| 20210300840 | PROCESS FOR PRODUCING ACETYLENE AND ETHYLENE - A process for producing acetylene, ethylene, or both is disclosed. The process includes combusting a fuel stream to produce a combustion gas effluent stream and pyrolyzing a feed stream in a pyrolysis zone in the presence of the combustion gas effluent stream to produce a pyrolysis zone effluent stream which is further quenched and compressed. The compressed quenched stream is separated in a solvent separation column to produce a net gas stream comprising hydrogen, methane, and at least one carbon oxide and a product stream. A portion of the carbon oxide of the net gas stream is converted into methane in a methanation reactor and a reactor effluent stream is sent to an amine scrubber where carbon dioxide is removed and a methane containing stream is generated as an effluent. The methane containing stream is then recycled to the pyrolysis zone of the supersonic reactor. | 2021-09-30 |
| 20210300841 | METHOD FOR PURIFYING ISOBUTENE FROM A C4 STREAM AND PROCESS SYSTEM THEREFOR - A process for the purification of isobutene from a C4 stream with at least 1-butene, 2-butene, isobutane and isobutene includes isomerizing 1-butene from a stream of material which is concentrated in isobutane and isobutene obtained from the C4 stream into 2-butene, using a catalyst in an isomerization reactor; supplying a product stream from the isomerization reactor to a rectification column; and providing a stream of material which is concentrated in isobutene. A processing facility is utilized for the purification of isobutene from the C4 stream. | 2021-09-30 |
| 20210300842 | Methods And Catalysts For Selective Olefin Isomerization - Zeolitic and molecular organic framework materials as catalysts suitable for generating branched olefins from linear olefins, thereby increasing the octane of a composition comprising the linear olefins. In particular, catalyst may exhibit selectivity for methyl-shift isomerization over cracking, alkylation, and oligomerization. | 2021-09-30 |
| 20210300843 | METHOD TO PRODUCE BIO-RENEWABLE PROPYLENE FROM OILS AND FATS - A method is disclosed for upgrading a bio-based material, the method including pretreating bio-renewable oil(s) and/or fat(s) to provide a bio-renewable raw material, deoxygenating the bio-renewable raw material, followed by separation, to provide a propane feed, and subjecting the propane feed to dehydrogenation and to separation to provide a propylene material. | 2021-09-30 |
| 20210300844 | ETHYNYL DERIVATIVES - The present invention relates to ethynyl derivatives of formula I | 2021-09-30 |
| 20210300845 | FUNCTIONALIZED POLYCYCLIC AROMATIC HYDROCARBON COMPOUND AND LIGHT-EMITTING DEVICE INCLUDING THE SAME - Provided are a functionalized polycyclic aromatic hydrocarbon compound and a light-emitting device including the same. The functionalized polycyclic aromatic hydrocarbon compound is structurally stable, and exhibits high light-emission characteristics since aggregation caused by π-π stacking is inhibited, and thus may have high efficiency and long lifespan characteristics. | 2021-09-30 |
| 20210300846 | AEROSOL COMPOSITIONS CONTAINING FLUORINE SUBSTITUTED OLEFINS AND METHODS AND SYSTEMS USING SAME - Various compostions, including particularly aerosol compositions, containing fluorinated olefins, including particularly tetra- and penta-fluorpropenes, in a variety of applications are disclosed. | 2021-09-30 |
| 20210300847 | METHOD FOR PRODUCING CYCLOBUTANEDIOL COMPOUND - Provided is a process in which a cyclobutanediol compound having a high cis:trans ratio can be stably obtained. The cyclobutanediol compound having a cis:trans ratio of 1.5:1 to 5000:1 is produced by using at least one compound selected from a group consisting of a cyclobutanedione compound, a cyclobutanketol compound, and a cyclobutanediol compound as a raw material, and performing a catalytic hydrogenation reaction and an isomerization reaction in the cyclobutanediol compound in a solid phase state in the presence of a metal catalyst without adding a solvent. | 2021-09-30 |
| 20210300848 | CATALYSTS FOR PRODUCING ALCOHOLS AND ETHERS FROM SYNTHESIS GAS - Catalysts for the production of an alcohol and/or an ether from synthesis gas, methods of making the catalysts, and uses thereof are described. The catalyst can include catalytic Cu metal particles or oxides thereof and/or Ni metal particles or oxides thereof on an alkali metal or alkaline earth metal silicate support. | 2021-09-30 |
| 20210300849 | PROCESS FOR PRODUCING METHANOL - A method for producing methanol is disclosed. The method includes supplying a high oxygen content oxidant to combust hydrocarbons, in particular methane, and then using the resulting hot gases to heat natural gas so as to convert the natural gas to synthesis gas. The synthesis gas is used to produce methanol in a methanol synthesis reactor. At least some of the carbon dioxide from the hot gases is fed to the methanol synthesis reactor to make methanol. | 2021-09-30 |
| 20210300850 | Systems and Methods for Purifying Solvents - The present disclosure is directed to methods and systems of purifying solvents. The purified solvents can be used for cleaning a semiconductor substrate in a multistep semiconductor manufacturing process. | 2021-09-30 |
| 20210300851 | Systems and Methods for Purifying Solvents - The present disclosure is directed to methods and systems of purifying solvents. The purified solvents can be used for cleaning a semiconductor substrate in a multistep semiconductor manufacturing process. | 2021-09-30 |
| 20210300852 | PROCESS AND PLANT FOR PRODUCING PURE METHANOL - The invention relates to a process and a plant for producing pure methanol, wherein the crude methanol stream discharged from a methanol synthesis unit is decompressed in a decompression vessel, is subsequently at least partially freed of low-boiling by-products in a prerun column and is then supplied to a single- or multi-stage methanol purification apparatus from which a pure methanol product stream is finally discharged. According to the invention the tops product stream from the prerun column is subjected to a scrubbing step with a methanol-selective scrubbing medium, thus at least partially recovering methanol present and sending a methanol-depleted tops product stream to the offgas disposal apparatus. | 2021-09-30 |
| 20210300853 | ACCESS TO CHIRAL BISPHENOL (BPOL) LIGANDS THROUGH DESYMMETRIZING ASYMMETRIC ORTHO-SELECTIVE MONO-HALOGENATION - The subject invention pertains to a method of halogenating phenols, yielding a range of halogenated phenols with enantiomeric ratio of up to 99.5:0.5. In certain embodiments, the subject invention pertains to a method of asymmetric halogenation of bisphenol, yielding a range of chiral bisphenol ligands. The novel chiral bisphenols are potent privileged catalyst cores that can be applied to the preparation of ligands for various catalytic asymmetric reactions. The catalyst library can easily be accessed because late-stage modification of the scaffold can readily be executed through cross-coupling of the halogen handles on the bisphenols. | 2021-09-30 |
| 20210300854 | PROCESS FOR PREPARING A FORMYLALKENYL ALKOXYMETHYL ETHER COMPOUND AND PROCESSES FOR PREPARING CONJUGATED DIENE COMPOUNDS FROM THE SAME - The present invention provide for preparing a formylalkenyl alkoxymethyl ether compound of the following general formula (2): R | 2021-09-30 |
| 20210300855 | SYNTHESIS OF BRANCHED ALKYL ALCOHOLS BY CU(I)-CATALYZED C-C COUPLING BETWEEN ALKYL GRIGNARD REAGENTS AND ALKYL TOSYLATES - A method includes: providing a mixture including at least one alkyl tosylate and a Grignard reagent; and reacting the at least one alkyl tosylate with the Grignard reagent in a C—C coupling reaction mechanism to form a branched aliphatic alcohol. | 2021-09-30 |
| 20210300856 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF BILASTINE - The invention relates to a process for preparing a compound of (III) | 2021-09-30 |
| 20210300857 | METHOD FOR PURIFYING (METH)ACRYLIC ESTERS - The invention relates to the production of (meth)acrylic esters according to a continuous process by transesterification, and in particular to the purification of a crude reaction mixture comprising a C | 2021-09-30 |
| 20210300858 | METHOD FOR PRODUCING CARBONIC ESTERS - The present invention relates to a process for providing carbonic acid esters of formula (I). Further, the invention relates to the intermediates of the formula (IVa). | 2021-09-30 |
| 20210300859 | ROSMARINIC ACID DERIVATIVE OR SALT THEREOF - The present invention provides a compound that inhibits the activity of TRPV4 and is useful for prevention or amelioration of an overactive bladder, an irritable bowel syndrome, etc. The compound is a rosmarinic acid derivative represented by the following formula (I) or a salt thereof: | 2021-09-30 |
| 20210300860 | Composition for Removing Polymer - Disclosed is a composition for removing polymers. The composition contains a fluorinated alkyl compound, a polar aprotic solvent, and an acyclic secondary or tertiary amine compound. | 2021-09-30 |
| 20210300861 | DRUG CRYSTALLIZATION UNDER MICROGRAVITY CONDITIONS - Disclosed is a method for crystallizing molecules having a molecular weight equal to or lower than about 500 Dalton in a gravity below about 0.01 g to about 0.000001 g as well as to crystalline molecules having a molecular weight equal to, or lower than, about 500 Dalton, prepared under microgravity conditions. | 2021-09-30 |
| 20210300862 | PROCESSES AND SYSTEMS FOR USING SILICA PARTICLES IN FLUID BED REACTOR - The present disclosure relates to fluid bed processes that utilize silica particles as a fluidization aid. The process comprises reacting one or more reactants in a reactor comprising a fluid bed to form a product. The fluid bed comprises a catalyst composition comprising a catalyst and an inert additive composition comprising silica particles from 0.5 wt % to 30 wt %, based on the total weight of the catalyst composition. The silica particles are discrete, inert particles that are mixed with the catalyst in the fluid bed. | 2021-09-30 |
| 20210300863 | PROCESS TO MAKE A SELECTIVE CATHEPSIN CYSTEINE PROTEASE INHIBITOR - A method of preparing a compound of Formula (I) comprising reacting the compound of Formula (A) with a base and a compound of Formula (B) to yield a compound of Formula (C). | 2021-09-30 |
| 20210300864 | PHOTOSTABILIZING COMPOUNDS, COMPOSITIONS, AND METHODS - Photostabilizing compounds are provided. In particular, the photostabilizing compound may be heterocyclic or homocyclic. Topical compositions comprising these photostabilizing compounds are also provided. In particular, these topical compositions further comprise photoactive compounds. Methods for stabilizing photoactive compounds are also provided. These methods comprise mixing the photoactive compounds with the photostabilizing compounds. | 2021-09-30 |
| 20210300865 | NOVEL ORGANIC SULFUR COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER OR AN INFLAMMATORY DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT - A novel organic sulfur compound, a method for preparing the same, and a pharmaceutical composition for preventing or treating cancer or inflammatory diseases, containing the same as an active ingredient are provided. The novel organic sulfur compound is capable of excellently inhibiting histone deacetylated (HDAC) enzymes in a concentration of nanomolar or micromolar units and has been found to have an excellent effect against inflammatory diseases, and has been found to be capable of inhibiting the proliferation of cancer. | 2021-09-30 |
| 20210300866 | CRYSTAL FORM OF KEY INTERMEDIATE OF BRUTON TYROSINE KINASE (BTK) INHIBITOR AND PREPARATION METHOD THEREOF - The present disclosure relates to a crystal form of a key intermediate of a bruton tyrosine kinase (BTK) inhibitor and a method for preparing the crystal form, and belongs to the technical field of medicine. The crystal form is a crystal form II of (R)-1-(1-(tert-butyloxyl)pyrrolidine-3-yl)-3-cyano-4-(4-(2,6-difluorophenoxyl)phenyl)-1H-pyrrole-2-ethyl formate. The obtained crystal form II of (R)-1-(1-(tert-butyloxyl)pyrrolidine-3-yl)-3-cyano-4-(4-(2,6-difluorophenoxyl)phenyl)-1H-pyrrole-2-ethyl formate has good chemical stability and crystal form stability and is convenient for storage and transportation. Meanwhile, the intermediate can be highly purified and a sample with a purity of 99.7% is obtained. The crystal form is important for quality control of a BTK inhibitor (R)-4-amino-1-(1-(butyl-2-alkynyl)pyrrolidine-3-yl)-3-(4-(2,6-difluorophenoxyl)phen yl)-1,6-dihydro-7H-pyrrolo[2,3-d]pyridazin-7-one, has a simple preparation process and is suitable for industrial production. | 2021-09-30 |
| 20210300867 | SELF-STABILIZING LINKER CONJUGATES - The present invention provides Ligand-Drug Conjugates, Drug-Linkers, Linkers, and Ligand-Linker Conjugates comprising a self-stabilizing linker assembly component. | 2021-09-30 |
| 20210300868 | SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS - The present invention concerns substituted indoline derivatives, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds. | 2021-09-30 |
| 20210300869 | MODULATORS OF ROR-GAMMA - Provided are indole, benzoimidazole, pyrrolopyridine, and imidazopyridine derivatives and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR | 2021-09-30 |
| 20210300870 | CRYSTALLINE N-METHYL TRYPTAMINE DERIVATIVES - Crystalline N-methyl tryptamine derivatives, compositions containing those crystalline forms and their methods of use are disclosed. The crystalline N-methyl tryptamine derivatives according to the invention include crystalline N-methyl-N-propyltryptamine (MPT), crystalline N-methyl-N-isopropyltryptammonium fumarate (MiPT fumarate) and crystalline 4-hydroxy-N-methyl-N-isopropyltryptammonium fumarate monohydrate (HO-MiPT fumarate monohydrate). | 2021-09-30 |
| 20210300871 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION - A compound: | 2021-09-30 |
| 20210300872 | SECOND GENERATION GRP94-SELECTIVE INHIBITORS - The present technology provides compounds selective for the Grp94 isoform, as well as compositions including such compounds, that are useful for treatment of multiple myeloma, melanoma, lung cancer, hepatocellular carcinoma, breast cancer, prostate cancer, and/or glaucoma. Methods using the compound are also provided. | 2021-09-30 |
| 20210300873 | STABLE POLYMORPHIC COMPOSITIONS OF BREQUINAR SODIUM AND METHODS OF USE AND MANUFACTURE THEREOF - The invention provides compositions containing a stable crystalline form of brequinar and methods of making such composition. The invention also provides methods of using such compositions to treat a condition in a subject. | 2021-09-30 |
| 20210300874 | ISOQUINOLINE-STEROID CONJUGATES AND USES THEREOF - Provided herein are compounds and pharmaceutical compositions useful in modulating kinase activity, and related diseases. Also provided herein are methods of treating an eye disease or disorder in a subject. Also provided herein are methods of reducing intraocular pressure in a subject. Also provided herein are methods of modulating kinase activity in a cell. Also provided herein are methods of making the compounds provided herein, and compounds useful for the preparation of the compounds provided herein. | 2021-09-30 |
| 20210300875 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF - Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity. | 2021-09-30 |
| 20210300876 | DIENE GEMINI POLYMERIZABLE SURFACTANTS WITH MIXED CIS AND TRANS ISOMERS THAT FORM BICONTINUOUS CUBIC PHASES - A polymerizable Gemini surfactant based on tail groups with mixed isomer dienes. The Gemini surfactants may be produced having imidazolium head groups and diene tail groups with a near-equal abundance of the “E” and “Z” isomers. These compounds are lyotropic liquid crystals that can form bicontinuous cubic phases by self-assembly. | 2021-09-30 |
| 20210300877 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES - A genus of compounds encompassed by formula (III) and their use is disclosed: | 2021-09-30 |
| 20210300878 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING - The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging. | 2021-09-30 |
| 20210300879 | PYRIMIDINYLOXY BENZENE DERIVATIVES AS HERBICIDES - Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof, | 2021-09-30 |
| 20210300880 | METHOD FOR PREPARING MACITENTAN AND INTERMEDIATE COMPOUND THEREOF - The present invention relates to technical field of chemical synthesis of drugs, and provides a preparation method of Macitentan and intermediate compound thereof. Adding. THF solution containing compound II and 5-bromo-2-chloropyrimidine slowly into THF solution containing base to react, or adding THF solution containing compound II and THF solution containing 5-bromo-2-chloropyrimidine slowly at the same time into THF solution containing base to react and obtain Macitentan (shown as compound I), wherein the base is selected from sodium hydride, potassium hydride, lithium hydride or lithium bis(trimethylsilyl)amide. The selectivity of the preparation method is very good, which is suitable for industrial production. The obtained product Macitentan has good quality and high yield. And the product compound II also has good quality and high yield, its HPLC purity is up to 99.0%, the content of impurity A is less than 0.20%, the content of impurity B is less than 0.25%. | 2021-09-30 |
| 20210300881 | SUBSTITUTED PHENYL SULFONYL PHENYL TRIAZOLE THIONES AND USES THEREOF - The present disclosure relates to substituted phenyl sulfonyl phenyl triazole thiones, pharmaceutical compositions containing them, and methods of using them. | 2021-09-30 |
| 20210300882 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF - Formulations and methods for reducing blood glucose and/or increasing insulin signaling in a subject have been developed. The formulations include SBI-477 and compounds based on SBI-477 i.e., SBI-477 analogs (collectively, SBI-477 compounds) and/or Mondo family inhibitors, in an effective amount to inhibit intracellular lipid accumulation and/or increase cellular glucose uptake when compared to levels in a control subject not administered the composition. Also disclosed are methods of reducing intracellular lipid accumulation and/or increase glucose uptake in a subject in need thereof. The method includes administering to the subject an effective amount of SBI-477 compounds and/or Mondo family inhibitor to reducing intracellular lipid accumulation and/or increase glucose uptake in the subject. Also disclosed are method for treating one or more Myc-driven cancers, including neuroblastoma, lung squamous cell carcinoma/lung adenocarcinoma, liver hepatocellular carcinoma, colon adenocarcinoma, acute myeloid leukemia, and breast invasive carcinoma. | 2021-09-30 |
| 20210300883 | SYNTHESIS METHOD FOR CARIPRAZINE - The present application relates to a synthesis method for cariprazine, comprising performing an acylation reaction between a compound represented by formula (I) and dimethylcarbamoyl chloride in a reaction solvent in the presence of an aqueous solution of an inorganic base, so as to obtain the cariprazine compound represented by formula (II). The synthesis method overcomes defects in the prior art such as a long reaction time, large size impurities and the difficulty of purification, and provides a new method suitable for commercial production wherein the reaction is fast, impurity sizes are small, the product is easily purified, the purity of the product can reach 99.0% or more, and the yield is high. | 2021-09-30 |
| 20210300884 | SYNTHESIS OF OLEOFURANS - Disclosed herein is a method for making oleofuran compounds according to formula 3 | 2021-09-30 |
| 20210300885 | METHOD FOR PRODUCING SCLAREOLIDE - A method for producing slcareolide comprising the following steps: (a) providing sclareol as starter material; (b) contacting the starter material sclareol with ozone in air or oxygen as the sole oxidant in an acidic medium. | 2021-09-30 |
| 20210300886 | SYNTHESIS OF INTERMEDIATES FOR THE PREPARATION OF ALPHA-TOCOPHEROL - The present invention relates to a novel synthetic pathway for alpha-tocopherol. The invention discloses different reactions yielding some new intermediates in a very high yield and stereoselectivity. | 2021-09-30 |
| 20210300887 | PRO-DRUGS OF ELIGLUSTAT - The present invention is directed to pro-drugs of Eliglustat (formula A) and process for the preparation thereof. The present invention is further directed to pharmaceutical composition thereof and method of treatment using the same. | 2021-09-30 |
| 20210300888 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING SAME AND ELECTRONIC DEVICE THEREFOR - Disclosed is a compound represented by chemical formula (1). In addition, disclosed is an organic electronic element comprising: a first electrode; a second electrode; and an organic layer between the first electrode and the second electrode, wherein the organic layer contains the compound represented by chemical formula (1). Light-emitting efficiency, stability and lifespan may be enhanced when the compound represented by chemical formula (1) is contained in the organic layer. | 2021-09-30 |
| 20210300889 | METHOD FOR PREPARING ARTIFICIALLY SYNTHETIC (R,S)-NICOTINE SALT - The present invention discloses a method for preparing an artificially synthetic (R,S)-nicotine salt, comprising: S1, reacting 4-methylamino-1-(3-pyridine)-butanone hydrochloride and an alkaline substance at −5 to 5° C.; S2, concentrating a reactant obtained in step S1, and adding a first refining solvent for refining to obtain 1-methyl-2-(3-pyridine)-2-pyrrolidinol; S3, adding a reducing agent into 1-methyl-2-(3-pyridine)-2-pyrrolidinol, and reacting at 15 to 35° C.; and S4, concentrating a reactant obtained in step S3, adding a second refining solvent for refining, and then adding an acid for reaction, to obtain the artificially synthetic (R,S)-nicotine salt. The present invention innovatively proposes a two-step method to synthesize the (R,S)-nicotine salt, and the prepared (R,S)-nicotine salt does not contain any other harmful tobacco compounds. The method of the present invention is simple in process, high in product, and suitable for large-scale industrial production. | 2021-09-30 |
| 20210300890 | Compounds Useful for Treating Liver Diseases - This invention provides compounds, for example, of Formulae (A)-(H) and (J)-(AA) and pharmaceutically acceptable salts, solvates, esters, amides, and prodrugs thereof. The invention further provides pharmaceutical compositions comprising a compound of the invention, and a pharmaceutically acceptable carrier or vehicle. The compounds and compositions disclosed herein are useful for treating or preventing various diseases and conditions, for example liver disease such as liver fibrosis, fatty liver disease, non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH), and kidney diseases such as acute kidney injury (AKI). | 2021-09-30 |
| 20210300891 | SALTS OF AN LSD1 INHIBITOR AND PROCESSES FOR PREPARING THE SAME - The present invention relates to processes and intermediates for preparing 3-(cyanomethyl)-3-(4-{[(1R,2S)-2-phenylcyclopropyl]amino}piperidin-1-yl)azetidine-1-sulfonamide, and salts and solid forms thereof, which selectively modulate demethylase. Particular embodiments contemplate compounds and disease indications amenable to treatment by modulation of lysine specific demethylase-1 (LSD1). | 2021-09-30 |
| 20210300892 | ETORICOXIB SOLVATES AND PREPARATION METHOD THEREOF - The disclosure relates to etoricoxib solvates and a preparation method thereof. A solvent is a hydrogen bond donor solvent with a polarity value π* ranging from 60 to 100 or a hydrogen bond acceptor solvent with a polarity value π* ranging from 92 to 100. Solvents with a polarity value π* within the above range all can form corresponding etoricoxib solvates with etoricoxib. The etoricoxib solvate can be prepared by cooling crystallization or suspension crystallization. A 1,2-propanediol solvate of etoricoxib and a dimethyl sulfoxide (DMSO) solvate of etoricoxib provided in the present disclosure have high thermal stability, unique crystal form, large size, concentrated distribution, and prominent flowability and is safe, pharmaceutically acceptable, and not easy to agglomerate. Compared with etoricoxib, the etoricoxib solvates exhibit significantly improved solubility. Moreover, preparation of the solvates requires low consumption in time, energy, and solvent, and has high efficiency, with a molar yield higher than 90%. | 2021-09-30 |
| 20210300893 | CRYSTALLINE FORMS OF ARN-509, PREPARATION METHOD AND USE THEREOF - The present disclosure relates to novel crystalline forms of ARN-509 (structure shown in formula I), processes for preparation of the novel crystalline forms, pharmaceutical composition of the novel crystalline forms, and uses of the novel crystalline forms for preparing drug products of androgen receptor antagonists and for treating prostate cancer. The crystalline forms of ARN-509 provided by the present disclosure have one or more improved properties compared with the prior art, and is of great value to the future optimization and development of drugs. | 2021-09-30 |
| 20210300894 | CRYSTALLINE FORM OF N-[1-(5-CYANO-PYRIDIN-2-YLMETHYL)-1 H-PYRAZOL-3-YL]-2-[4-(1-TRIFLUO-ROMETHYL-CYCLOPROPYL)-PHENYL]-ACETAMIDE - The present invention relates to crystalline forms of N-[1-(5-cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, pharmaceutical compositions comprising said crystalline forms and their use as T-type calcium channel blockers in the treatment or prevention of diseases or disorders where T-type calcium channels are involved. | 2021-09-30 |
| 20210300895 | DEUTERATED (S)-2-(4-(PIPERIDIN-3-YL)PHENYL)-2H-INDAZOLE-7-CARBOXAMIDE - A deuterated compound having the structure of Formula I: or a pharmaceutically acceptable salt, solvate, or prodrug thereof; or a salt of a prodrug thereof; or a hydrate or polymorph thereof; wherein Y | 2021-09-30 |
| 20210300896 | METHOD FOR PRODUCING OPTICALLY ACTIVE PYRROLIDINE COMPOUNDS - The present invention provides a process for preparing a compound represented by formula (VII), which comprises reacting a compound represented by formula (VI) with a malonic acid derivative in the presence of a base and an asymmetric catalyst in a two layer solvent system of hydrophobic solvent and water. | 2021-09-30 |
| 20210300897 | CRYSTALLINE FORMS OF A LTA4H INHIBITOR - This application relates to various crystalline forms of (S)-3-amino-4-(5-(4-((5-chloro-3-fluoropyridin-2-yl)oxy)phenyl)-2H-tetrazol-2-yl)butanoic acid in its free form, as well as compositions, method of making and methods of using the same. In some embodiments the crystalline forms also contain water (“hydrates”). These materials are useful in the treatment of diseases and disorders which are typically ameliorated by the inhibition of LTA4H. Such diseases and disorders may include inflammatory and autoimmune disorders and pulmonary and respiratory tract inflammation. | 2021-09-30 |
| 20210300898 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS - Disclosed are compounds, compositions, and methods useful for treating or preventing a disease or disorder associated with a mutation in a protein. | 2021-09-30 |
| 20210300899 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS - The present invention provides, in part, compounds of Formula I: | 2021-09-30 |
| 20210300900 | OGA INHIBITOR COMPOUNDS - The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations. | 2021-09-30 |
| 20210300901 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF - The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions. In some embodiments, the compounds disclosed herein exhibit androgen receptor degradation activity. | 2021-09-30 |
| 20210300902 | OPTICALLY ACTIVE PYRROLIDINE COMPOUND AND METHOD FOR PRODUCING SAME - The present invention provides: a methyl 1-{2-[(3S,4R)-1-[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidine-3-carbonyl]-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylate 1/2 ethane-1,2-disulfonic acid which is represented by formula (1) and is excellent in crystallinity; and a method for producing the same; and a production intermediate thereof; and a production method using this compound. | 2021-09-30 |
| 20210300903 | SIGMA RECEPTOR BINDERS - Provided herein, inter alia, are compounds and methods of treating diseases including cancer, neurological disease, alcohol withdrawal, depression and anxiety, and neuropathic pain. | 2021-09-30 |
| 20210300904 | INHIBITORS OF RAF KINASES - Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases. | 2021-09-30 |
| 20210300905 | INHIBITING ATAXIA TELANGIECTASIA AND RAD3-RELATED PROTEIN (ATR) - Novel compounds inhibiting ATR protein kinase include compounds of formula (I) disclosed herein, as well as liposome formulations comprising ATR protein kinase inhibitor compounds. The compositions are useful for the treatment of cancer. | 2021-09-30 |
| 20210300906 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS - The disclosures herein relate to novel compounds of formula (1): and salts thereof, wherein A; X; n; R | 2021-09-30 |
| 20210300907 | COMPOUNDS CONTAINING BENZO[D][1,3]OXATHIOLE, BENZO[D][1,3]OXATHIOLE 3-OXIDE OR BENZO[D][1,3]OXATHIOLE 3,3-DIOXIDE AND METHODS/USES THEREOF AS AGONISTS OF G PROTEIN-COUPLED RECEPTOR 119 - There are provided compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide, and benzo[d][1,3]oxathiole 3,3-dioxide, as well as uses/methods related thereto, including treatment of diseases and condition associated with GPR119 dysregulation, Type 2 diabetes mellitus, and related metabolic disorders. | 2021-09-30 |
| 20210300908 | S1P1 AGONIST AND APPLICATION THEREOF - The present invention relates to a class of tricyclic compounds and an application thereof as a sphingosine 1-phosphate type 1 (S1P1) receptor agonist. The invention specifically relates to a compound represented by formula (II), and a tautomer and pharmaceutically acceptable salt of same. | 2021-09-30 |
| 20210300909 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF - The present invention relates to compounds of Formula I, methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections. | 2021-09-30 |
| 20210300910 | PHEBOX LIGANDS AND METHODS OF MAKING SAME - The present disclosure provides compounds which are useful for a number of catalytic transformations of organic molecules, non-limiting examples including dehydrogenation of alkanes. The present disclosure further relates to methods of preparing the compounds of the present disclosure. | 2021-09-30 |
| 20210300911 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) - The present invention provides novel compounds according to Formula (I): | 2021-09-30 |
| 20210300912 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF - The present invention provides AHR agonists, compositions thereof, and methods of using the same. | 2021-09-30 |
| 20210300913 | DEUTERATED DERIVATIVES OF LANIFIBRANOR - The present invention relates to deuterated derivatives of lanifibranor, in particular for use in therapy, specifically in the treatment of fibrotic diseases. | 2021-09-30 |
| 20210300914 | SUBSTITUTED PYRIMIDINES AS LRKK2 INHIBITORS - The present disclosure relates generally to compounds of formula (I) | 2021-09-30 |
| 20210300915 | BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF - The invention provides various novel compositions of berberine in combination with pharmacologically active organic acids, and related methods of their use in treating various diseases or disorders. The invention further provides various novel compounds prepared from berberine and pharmacologically active organic acids and prepared from ursodeoxycholic acid and pharmacologically active organic bases, and pharmaceutical compositions thereof, and methods of their preparation and therapeutic use in treating and/or preventing various diseases or disorders. The compounds and pharmaceutical compositions of the invention can be utilized to treat various diseases or disorders, such as diabetes, diabetic complications, dyslipidemia, hyperlipidemia, obesity, metabolic syndromes, pre-diabetes, atherosclerosis, heart diseases, neurodegenerative diseases, sarcopenia, muscle atrophy, inflammation, cancer and liver diseases and conditions such as fatty liver, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, cholestatic liver diseases or graft-versus-host disease of the liver. The compounds of this invention are also useful in improving liver functions in chronic viral associated liver diseases and alcohol-related liver diseases. | 2021-09-30 |
| 20210300916 | NITROGENOUS HETEROCYCLIC AROMATIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION THEREOF - Provided are a nitrogenous heterocyclic aromatic compound, a preparation method therefor, a pharmaceutical composition thereof, and an application thereof. The nitrogenous heterocyclic aromatic compound can be used for treating and/or preventing various diseases mediated by ALK5. | 2021-09-30 |
| 20210300917 | Solid State Forms of an Apoptosis-Inducing Agent and Processes Thereof - Various crystalline and amorphous solid state forms of an apoptosis-inducing agent and preparations thereof are disclosed. Also discloses the use of crystalline forms for the preparation of amorphous form of apoptosis-inducing agent. Further discloses a process for preparation of the apoptosis-inducing agent. (Formula I) | 2021-09-30 |
| 20210300918 | SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE - The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes. | 2021-09-30 |
| 20210300919 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 - The present invention relates to compounds of formula I: | 2021-09-30 |
